Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 3Sarcoma 2Plasma cell 2Head & Neck 2Gastrointestinal 2Dermatologic 2CNS 2Breast 2Thoracic 1Genitourinary 1

Conditions

Brain Neoplasms 24Melanoma 19Glioblastoma 13Neuroblastoma 6Glioma 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Wilms Tumor 2Seminoma 2Rhabdomyosarcoma 2Osteosarcoma 2Neoplasm Metastasis 2Meningioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hodgkin Disease 2Gliosarcoma 2Central Nervous System Neoplasms 2Astrocytoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1

Interventions

Filgrastim 11Temozolomide 9Melphalan 9Cyclophosphamide 9Radiotherapy 7Busulfan 7Magnetic Resonance Spectroscopy 6Rituximab 5Psychiatric Rehabilitation 5Methotrexate 5Etoposide 5Cytarabine 5Carboplatin 5sargramostim 4fludarabine 4etoposide phosphate 4Thiotepa 4Nivolumab 4Methylprednisolone 4Flow Cytometry 4Alemtuzumab 4Vincristine 3Topotecan 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Pemetrexed 3Granulocyte Colony-Stimulating Factor 3Early Intervention, Educational 3Drug Therapy 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × Ipilimumab × CNS × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

NCT01445379 2019-12-17

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
33 enrolled
CNSGenitourinaryLymphoidSarcoma

Lymphoma, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡